TY - JOUR
T1 - Gadolinium-conjugated TiO2-DNA oligonucleotide nanoconjugates show prolonged intracellular retention period and T1-weighted contrast enhancement in magnetic resonance images
AU - Paunesku, Tatjana
AU - Ke, Tianyi
AU - Dharmakumar, Rohan
AU - Mascheri, Nicole
AU - Wu, Aiguo
AU - Lai, Barry
AU - Vogt, Stefan
AU - Maser, Jörg
AU - Thurn, Kenneth
AU - Szolc-Kowalska, Barbara
AU - Larson, Andrew
AU - Bergan, Raymond C.
AU - Omary, Reed
AU - Li, Debiao
AU - Lu, Zheng Rong
AU - Woloschak, Gayle E.
PY - 2008/9
Y1 - 2008/9
N2 - Nanoconjugates composed of titanium dioxide (TiO2) nanoparticles, DNA oligonucleotides, and a gadolinium (Gd) contrast agent were synthesized for use in magnetic resonance imaging. Transfection of cultured cancer cells with these nanoconjugates showed them to be superior to the free contrast agent of the same formulation with regard to intracellular accumulation, retention, and subcellular localization. Our results have shown that 48 hours after treatment, the concentration of Gd in nanoconjugate-treated cells was 1000-fold higher than in cells treated with contrast agent alone. Consequently, T1-weighted contrast enhancements were observed in cells treated with nanoconjugates but not in cells treated by the contrast agent alone. This type of nanoconjugate with increased retention time, Gd accumulation, and intracellular delivery may find its use in Gd neutron-capture cancer therapy.
AB - Nanoconjugates composed of titanium dioxide (TiO2) nanoparticles, DNA oligonucleotides, and a gadolinium (Gd) contrast agent were synthesized for use in magnetic resonance imaging. Transfection of cultured cancer cells with these nanoconjugates showed them to be superior to the free contrast agent of the same formulation with regard to intracellular accumulation, retention, and subcellular localization. Our results have shown that 48 hours after treatment, the concentration of Gd in nanoconjugate-treated cells was 1000-fold higher than in cells treated with contrast agent alone. Consequently, T1-weighted contrast enhancements were observed in cells treated with nanoconjugates but not in cells treated by the contrast agent alone. This type of nanoconjugate with increased retention time, Gd accumulation, and intracellular delivery may find its use in Gd neutron-capture cancer therapy.
KW - Magnetic resonance imaging
KW - Nanoconjugates
KW - Subcellular targeting
UR - http://www.scopus.com/inward/record.url?scp=49649116088&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=49649116088&partnerID=8YFLogxK
U2 - 10.1016/j.nano.2008.04.004
DO - 10.1016/j.nano.2008.04.004
M3 - Article
C2 - 18567541
AN - SCOPUS:49649116088
SN - 1549-9634
VL - 4
SP - 201
EP - 207
JO - Nanomedicine: Nanotechnology, Biology, and Medicine
JF - Nanomedicine: Nanotechnology, Biology, and Medicine
IS - 3
ER -